Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies — a EuroFlow study

作者：Martijn W. C. Verbeek, Chiara Buracchi, Anna Laqua, Stefan Nierkens, Łukasz Sędek, Juan Flores‐Montero, Mattias Hofmans, Elaine Sobral de Costa, Michaela Nováková, Ester Mejstříková, Susana Bárrena, Saskia Kohlscheen, Monika Szczepanowski, Jan Kulis, Elen Oliveira, Romana Jugooa, Anja X. De Jong, Tomasz Szczepański, Jan Philippé, Jacques J. M. van Dongen, Alberto Órfão, Monika Brüggemann, Giuseppe Gaipa, Vincent H. J. van der Velden · 发表于：British Journal of Haematology · 年份：2021 · DOI：10.1111/bjh.17992 · 被引用次数：17 · 研究领域：Acute Lymphoblastic Leukemia research、Childhood Cancer Survivors' Quality of Life、Lymphoma Diagnosis and Treatment

The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.